Skip to Content
Merck
All Photos(1)

Documents

P2120000

Piretanide

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

4-Phenoxy-3-(1-pyrrolidinyl)-5-sulfamoylbenzoic acid

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C17H18N2O5S
CAS Number:
55837-27-9
Molecular Weight:
362.40
UNSPSC Code:
41116107
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

piretanide

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

InChI

1S/C17H18N2O5S/c18-25(22,23)15-11-12(17(20)21)10-14(19-8-4-5-9-19)16(15)24-13-6-2-1-3-7-13/h1-3,6-7,10-11H,4-5,8-9H2,(H,20,21)(H2,18,22,23)

InChI key

UJEWTUDSLQGTOA-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Piretanide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Effect of Na/K/2Cl transporter inhibition with piretanide on postischemic kidney function.
D Abendroth et al.
Transplantation proceedings, 28(1), 83-84 (1996-02-01)
[Study report: Hypertension therapy with organ protection. Piretanid and Ramipril: advantages with fixed combination].
Fortschritte der Medizin. Supplement : die Kongressinformation fur die Praxis, 164, 3-15 (1994-01-01)
Nadia F Youssef
Journal of pharmaceutical and biomedical analysis, 39(5), 871-876 (2005-10-15)
Stability-indicating high performance liquid chromatography (HPLC), thin-layer chromatography (TLC) and first-derivative of ratio spectra (1DD) methods are developed for the determination of piretanide in presence of its alkaline induced degradates. HPLC method depends on separation of piretanide from its degradates
H M Cox et al.
British journal of pharmacology, 113(4), 1243-1248 (1994-12-01)
1. The secretory responses to calcitonin gene-related peptide (CGRP) receptor agonists have been characterized in two human adenocarcinoma cell lines, namely HCA-7 and Colony-29 (Col-29) epithelia. These cells form polarized epithelial layers when grown on permeable supports and allow changes
R A Brown et al.
Journal of vascular research, 36(6), 492-501 (2000-01-12)
The inhibition by loop diuretics of K efflux (tracer (86)Rb) from the rat femoral arterial smooth muscle was measured in normotension and in DOCA-salt hypertension. The sensitivity sequence (bumetanide > piretanide > furosemide) was the characteristic pharmacological profile of (Na+K+Cl)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service